$LXRX
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Healthcare
Sector
Biotechnology
Industry
Michael S. Exton
CEO
103
Employees
$1.62
Current Price
$601.11M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 2 | $149,980.00 | 102,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 2 | 8 | $2,722,624.64 | 2,058,959 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 2 | 8 | $2,722,624.64 | 2,058,959 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | DEBBANE RAYMOND Director | Purchase | 2,000 | $1.49 | $2,980.00 | View Details |
| Feb 23, 2026 | DEBBANE RAYMOND Director | Purchase | 100,000 | $1.47 | $147,000.00 | View Details |
| Feb 19, 2026 | DEBBANE RAYMOND Director | Purchase | 50,000 | $1.44 | $71,965.00 | View Details |
| Feb 20, 2026 | DEBBANE RAYMOND Director | Purchase | 100,000 | $1.48 | $147,790.00 | View Details |
| Feb 18, 2026 | DEBBANE RAYMOND Director | Purchase | 133,688 | $1.32 | $176,468.16 | View Details |
| Feb 13, 2026 | DEBBANE RAYMOND Director | Purchase | 57,952 | $1.31 | $75,876.55 | View Details |
| Feb 17, 2026 | DEBBANE RAYMOND Director | Purchase | 76,857 | $1.31 | $100,544.33 | View Details |
| Feb 2, 2026 | Invus Global Management, LLC Director | Purchase | 1,538,462 | $1.30 | $2,000,000.60 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.07
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history